House Backs Funding for Justice Department Tobacco Lawsuit

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 8
Volume 9
Issue 8

WASHINGTON-The House voted to allow the Justice Department to tap funds from three other federal departments to help pay for pursuing a lawsuit against the tobacco industry. Attorney General Janet Reno had said that without funds from the Departments of Health and Human Services, Defense, and Veterans’ Affairs, the government would be unable to go forward with the suit to recover $20 billion in federal funds spent on treating tobacco-related illnesses.

WASHINGTON—The House voted to allow the Justice Department to tap funds from three other federal departments to help pay for pursuing a lawsuit against the tobacco industry. Attorney General Janet Reno had said that without funds from the Departments of Health and Human Services, Defense, and Veterans’ Affairs, the government would be unable to go forward with the suit to recover $20 billion in federal funds spent on treating tobacco-related illnesses.

Articles in this issue
Irinotecan Plus Cisplatin May Be a Promising Radiation Sensitizer, According to Phase II Study
Major Trial of Four Newest Chemotherapy Regimens for Advanced NSCLC Shows Comparable Survival
Irinotecan-Containing Chemotherapy Regimens Active in Pancreatic Cancer and Ovarian Cancer
Interim Results Show Similar Response Rates for TEC vs CEV in Small-Cell Lung Cancer
Scientists Identify Gene Mutations in Multiple Myeloma
Irinotecan Plus Cisplatin Results in Highly Significant Survival Improvement in Extensive-Disease Small-Cell Lung Cancer
New Analyses Establish the Addition of Irinotecan to Fluorouracil/Leucovorin as the New Standard of Care for First-Line Rx of Metastatic Colorectal Cancer
Single-Agent Herceptin Active in Metastatic Breast Cancer
Brain Metastases Respond to Paclitaxel, Carboplatin, and Brain RT
AC Comparable to CMF in ER-Negative, Node-Negative Early-Stage Breast Cancer
Herceptin/Vinorelbine Promising in Metastatic Breast Cancer
Early Phase III Results Indicate Concurrent Chemoradiation Is Promising for Treatment of Locally Advanced NSCLC
Gemcitabine/Vinorelbine Boosts Survival in Elderly NSCLC Patients
Timing Affects Chemotherapy’s Effectiveness and Tolerability in Metastatic Colon Cancer
Virtual Colonoscopy Promising for Colon Cancer Screening
Related Videos
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Related Content
The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer

April 19th 2024
Article

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024
Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

FDA Approves Alectinib for Early-Stage ALK+ NSCLC

FDA Approves Alectinib for Early-Stage ALK+ NSCLC

April 18th 2024
Article

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.

Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.

Pembrolizumab Prolongs Survival in Clear-Cell RCC

April 18th 2024
Article

Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.